If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
ROCKVILLE, Md., June 23 (HSMN NewsFeed) — MacroGenics, Inc. announced today that Mr. Paulo F. Costa has been elected to the company’s Board as an independent director. Mr. Costa is the former President and Chief Executive Officer of Novartis U.S. Corpor…
Biopharmaceuticals, Personnel
MacroGenics
Posts from ‘June, 2009’
Paulo F. Costa Joins MacroGenics Board of Directors
Abbott Receives CE Mark for Company’s Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Job
Broad Size Matrix of XIENCE PRIME to be Launched in Europe in the Third Quarter ABBOTT PARK, Ill., June 23 (HSMN NewsFeed) — Abbott announced today that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolim…
Devices, Interventional Cardiology, Regulatory
Abbott, XIENCE PRIME, XIENCE, drug eluting stent
ConforMIS Receives CE Mark for the First and Only Personalized Bicompartmental Knee Resurfacing System
Innovative iDuo(R) Knee Implant and iJig(R) Instrumentation Approved For Use in European Union BURLINGTON, Mass.–(HSMN NewsFeed)–ConforMIS, Inc., a privately held orthopedics company that develops and commercializes personalized, minimally invasive me…
Devices, Orthopaedic, Regulatory
ConforMIS, iDuo , bicompartmental knee, resurfacing implant
Edwards Lifesciences to Sell Its Hemofiltration Product Line to Baxter
June 23, 2009 -(HSMN NewsFeed)- Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, announced today that it has entered into a definitive agreement with Baxter International Inc. to sell certain as…
Devices, Acquisitions
Edwards Lifesciences, Baxter, continuous renal replacement therapy
Synergy(R), CircuLite’s Micro-Blood Pump, Shown to Provide Sustained Improvements in Cardiac Function and Evidence of Myocardial Recovery in Patients with Chronic Heart Failure
Publication in Journal of the American College of Cardiology Demonstrates Clinical Proof-of-concept and Will Support CE Mark Filing for Synergy for Long-term Partial Circulatory Support in Chronic Heart Failure SADDLE BROOK, N.J.–(HSMN NewsFeed)–Circu…
Devices, Cardiology
CircuLite, Synergy Pocket Micro-pump
Environmental Tectonics Corporation’s BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan
SOUTHAMPTON, Pa., June 22 (HSMN NewsFeed) — Environmental Tectonics Corporation’s (OTC Bulletin Board: ETCC ; "ETC" or the "Company") BioMedical Division today announced that the Japan Ministry of Health, Labor and Welfare (MHLW) has…
Devices, Regulatory
Environmental Tectonics, BARA-MED, hyperbaric chamber
CoAxia, Inc. Announces $21.5M Series D Financing
Funding and Clinical Trial Progress Job Company for PMA Submission MINNEAPOLIS, June 22 (HSMN NewsFeed) — CoAxia, Inc. of Maple Grove, MN, announced today completion of a $21.5M Series D financing. The round was led by Sofinnova Senior partners with pa…
Devices, Neurology, Venture Capital
CoAxia, NeuroFlo catheter, SENTIS trial, stroke, perfusion augmentation
Sechrist Industries Introduces Ground-Check System to Verify NFPA Ground Requirements in Hyperbaric Chambers
New Kit is First to Offer Full Integration with Patient and Chamber ANAHEIM, Calif., June 22 (HSMN NewsFeed) — Sechrist Industries, world leader in technology for hyperbaric healthcare, today announced the availability of a new Patient and Chamber Gr…
Devices, Wound Care
Sechrist Industries, Ground-Check, hyperbaric chamber
Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
SAN DIEGO, June 22 (HSMN NewsFeed) — Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ) announced today that Scott Byrd has joined the company as Senior Vice President and Chief Commercial Officer. Mr. Byrd will report directly to Ted Schroeder, President an…
Biopharmaceuticals, Personnel
Cadence Pharmaceuticals, Acetavance, intravenous acetaminophen
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
FRAZER, Pa., June 19 (HSMN NewsFeed) — Cephalon, Inc. (Nasdaq: CEPH ) today announced results from a pivotal medical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The st…
Biopharmaceuticals, Oncology
Cephalon, lestaurtinib, acute myelogenous leukemia
